Context Therapeutics (NASDAQ:CNTX) CEO Marty Lehr joins Natalie Stoberman from the Proactive newsroom to discuss its latest feature in top biotech newsletter STAT News on how the company is developing Claudin 6 as a promising oncology target.
Claudin 6 (CLDN6) is differentially expressed on cancer cells with no or very low expression in normal, healthy tissue. CLDN6-enriched cancers include ovarian, endometrial, testicular, and gastric, among others.
Context Therapeutics is a clinical-stage biopharmaceutical company committed to advancing medicines for solid tumors, with a primary focus on female cancers. The Company’s pipeline includes small molecule and bispecific antibody drug candidates that target cancer signaling pathways. This includes CTIM-76, a selective Claudin 6 x CD3 bispecific antibody for CLDN6 positive tumors, currently in preclinical development.